| Eastern Montana Community Mental Health Center | |
|
2508 Wilson St Miles City MT 59301-5000 | |
| (406) 234-1687 | |
| (406) 234-1698 |
| Full Name | Eastern Montana Community Mental Health Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 2508 Wilson St, Miles City, Montana |
| Authorized Official Name and Position | Kathy K Beason (CHIEF INFORMATION OFFICER) |
| Authorized Official Contact | 4062340234 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Eastern Montana Community Mental Health Center Po Box 1530 Miles City MT 59301-1530 Ph: (406) 234-0234 | Eastern Montana Community Mental Health Center 2508 Wilson St Miles City MT 59301-5000 Ph: (406) 234-1687 |
| NPI Number | 1992786784 |
|---|---|
| Provider Enumeration Date | 11/08/2005 |
| Last Update Date | 07/30/2020 |
| Certification Date | 07/30/2020 |
| Medicare PECOS PAC ID | 9032155601 |
|---|---|
| Medicare Enrollment ID | O20050705000923 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992786784 | NPI | - | NPPES |
| 0439212 | Medicaid | MT | |
| 0491470 | Medicaid | MT | |
| 0502418 | Medicaid | MT | |
| 0320112 | Medicaid | MT | |
| 0255527 | Medicaid | MT | |
| 0290147 | Medicaid | MT | |
| 75031 | Other | MT | BS/BS PROVIDER # |
| 0402142 | Medicaid | MT |
| Provider Name | Diane E Savage |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1740315480 PECOS PAC ID: 1456397967 Enrollment ID: I20050706001119 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Provider Name | Laura Wetherelt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689641052 PECOS PAC ID: 0648219956 Enrollment ID: I20060418000714 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Provider Name | Cody E Portwine Kinzer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1942461223 PECOS PAC ID: 0840441150 Enrollment ID: I20121114000600 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Provider Name | Melinda M Truesdell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023422763 PECOS PAC ID: 1557588662 Enrollment ID: I20140814000122 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Provider Name | Lindsey E Hoerner |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1437696028 PECOS PAC ID: 1052663606 Enrollment ID: I20181009001490 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Provider Name | Sheri Lynn Hilyard |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1164467833 PECOS PAC ID: 1153355136 Enrollment ID: I20190325001972 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
| Provider Name | Martha Carstensen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1275149122 PECOS PAC ID: 5991162778 Enrollment ID: I20230609001622 |
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
News Archive
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the fourth quarter and year ended December 31, 2010.
Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 1 days ago
Two Rivers Wellness Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2911 Wilson St, Miles City, MT 59301 Phone: 406-234-2929 Fax: 406-234-2928 | |
Eastern Montana Community Mental Health Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2508 Wilson St, Miles City, MT 59301 Phone: 406-234-0234 | |
Eastern Montana Community Mental Health Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2508 Wilson St, Miles City, MT 59301 Phone: 406-234-0234 | |
Essence Counseling Services Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 519 Main St, Miles City, MT 59301 Phone: 575-693-0167 | |
Glade Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 18 N 8th St Ste 1&2, Miles City, MT 59301 Phone: 406-234-0787 | |
Anna R Rapson Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 321 Main St Ste 5, Miles City, MT 59301 Phone: 406-853-4812 | |
East Prairie Consulting Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 519 Main St, Miles City, MT 59301 Phone: 406-853-5822 |